© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Wegovy: FDA-approved for the management of obesity in June 2021, this medication has gained widespread attention for its effectiveness in supporting weight loss. Zepbound: Recently FDA-approved in ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade. After a fallow period ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, according to the chief executive officer of Zealand Pharma A/S ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Many people on these weight-loss drugs - which include Ozempic, Wegovy, Zepbound and Mounjaro - report that they're shelling out more for clothes and a variety of other goods and services to fit ...

However, it's expected that insurance coverage for Zepbound will expand as insurance companies update their drug coverage rules. That's similar to what's happening with insurance coverage for another ...

Unlike some GLP-1 agonists, like Ozempic or Wegovy, Zepbound is also a GIP agonist. By activating this second hormone pathway, the medication may be even more effective for reducing food intake ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...